Molecular modeling studies of quinoline derivatives as VEGFR-2 tyrosine kinase inhibitors using pharmacophore based 3D QSAR and docking approach

Arabian Journal of Chemistry

Volumn 10, Issue , 2017, Pages S1980-S2003

  Ugale, Vinod G ^a   Patel, Harun M ^a   Surana, Sanjay J ^a  

^a R C PATEL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

Author keywords

3D QSAR, docking; Lipinski's rule of five; VEGFR 2 tyrosine kinase inhibitors

Indexed keywords

AMINO ACIDS; COMPLEXATION; CRYSTAL STRUCTURE; DRUG PRODUCTS; ENZYME INHIBITION; ENZYMES; HYDROGEN BONDS; MOLECULAR GRAPHICS; PHARMACODYNAMICS;

3D-QSAR; CORRELATION COEFFICIENT; DRUG-RECEPTOR INTERACTIONS; HYDROGEN BOND ACCEPTORS; LIPINSKI'S RULE OF FIVE; MOLECULAR MODELING STUDIES; PHARMACOPHORE MODELING; TYROSINE KINASE INHIBITOR;

COMPUTATIONAL CHEMISTRY;

EID: 84881297539     PISSN: 18785352     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arabjc.2013.07.026     Document Type: Article

References (43)

1. Anan, K., Morosaki, T., Katano, M., Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer. Surgery 119 (1996), 333–339.
2. Axe, F.U., Bembenek, S.D., Szalma, S., Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore. J. Mol. Graph Model. 24 (2006), 456–464.
3. Baka, S., Clamp, A.R., Jayson, G.C., A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opin. Ther. Targets 10 (2006), 867–876.
4. Brown, L.F., Berse, B., Jackman, R.W., Tognazzi, E.J., Manseau, D.R., Dvorak, H.F., Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. 53 (1993), 4727–4735.
5. Carmeliet, P., Jain, R.K., Angiogenesis in cancer and other diseases. Nature 407 (2000), 249–257.
6. Ciardiello, F., Bianco, R., Caputo, R., Damiano, V., Troiani, T., Melisi, D., De Vita, F., De Placido, S., Bianco, A.R., Tortora, G., Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin. Cancer Res. 10 (2004), 784–793.
7. Dixon, S.L., Smondyrev, A.M., Knoll, E.H., Rao, S.N., Shaw, D.E., Friesner, R.A., PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J. Comput.-Aided Mol. Des. 20 (2006), 647–671.
8. Escudier, B., Eisen, T., Stadler, W.M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A.A., Rolland, F., Demkow, T., Hutson, T.E., Gore, M., Freeman, S., Schwartz, B., Shan, M., Simantov, R., Bukowski, R.M., Sorafenib in advanced clearcell renal-cell carcinoma. N. Eng. J. Med. 49 (2009), 332–334.
9. Fan, T.P.D., Jaggar, R., Bicknell, R., Controlling the vasculature: angiogenesis, anti-angiogenesis, and vascular targeting of gene therapy. Trends Pharmacol. Sci. 16 (1995), 57–66.
10. Ferrara, N., VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2 (2002), 795–803.
11. Ferrara, N., Hillan, K.J., Gerber, H.P., Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3 (2004), 391–400.
12. Folkman, J., Angiogenesis in cancer, vascular, rheumtoid and other disease. Nat. Med. 1 (1995), 27–31.
13. Friesner, R.A., Banks, J.L., Murphy, R.B., Halgren, T.A., Klicic, J.J., Mainz, D.T., Repasky, M.P., Knoll, E.H., Shelley, M., Perry, J.K., Shaw, D.E., Francis, P., Shenkin, P.S., Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47 (2004), 1739–1749.
14. Golbraikh, A., Shen, M., Xiao, Z., Xiao, Y.D., Lee, K.H., Tropsha, A., Rational selection of training and test sets for the development of validated QSAR models. J. Comput. Aided Mol. Des. 17 (2003), 241–253.
15. Halgren, T.A., MMFF94 van der Waals and Electrostatic Parameters for Intermolecular Interactions. J. Comput. Chem., 17, 1996, 520.
16. Halgren, T.A., Murphy, R.B., Friesner, R.A., Beard, H.S., Frye, L.L., Pollard, W.T., Banks, J.L., Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 47 (2004), 1750–1759.
17. Holmes, K., Roberts, O.L., Thomas, A.M., Cross, M.J., Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal. 19 (2007), 2003–2012.
18. Klebl, B.M., Muller, G., Second-generation kinase inhibitors. Expert Opin. Ther. Targets 9 (2005), 975–993.
19. Kubo, K., Shimizu, T., Ohyama, S., Murooka, H., Iwai, A., Nakamura, K., Hasegawa, K., Kobayashi, Y., Takahashi, N., Takahashi, K., Kato, S., Izawa, T., Isoe, T., Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure activity relationships, and antitumor activities of N-phenyl-N′-{4-(4-quinolyloxy) phenyl} ureas. J. Med. Chem. 48 (2005), 1359–1366.
20. Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 23, 2001, 3.
21. Morabito, A., Piccirillo, M.C., Falasconi, F., De Feo, G., Del Giudice, A., Bryce, J., Di Maio, M., De Maio, E., Normanno, N., Perrone, F., Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 14 (2009), 378–390.
22. Motzer, R.J., Michaelson, M.D., Redman, B.G., Hudes, G.R., Wilding, G., Figlin, R.A., Ginsberg, M.S., Kim, S.T., Baum, C.M., DePrimo, S.E., Li, J.Z., Bello, C.P., Theuer, D.J., George, B.I., Rini, J., Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. Clin. Oncol. 24 (2006), 16–24.
23. Narkhede, S.S., Degani, M.S., Pharmacophore Refinement and 3D-QSAR Studies of Histamine H3 Antagonists. QSAR Comb. Sci. 26 (2007), 744–753.
24. Noolvi, M.N., Patel, H.M., 2D QSAR Studies on aseries of quinazoline derivatives as tyrosine kinase (EGFR) inhibitor: An approach to design anti-cancer agents. Lett. Drug Design Dis. 7 (2010), 556–586.
25. Noolvi, M.N., Patel, H.M., Bhardwaj, V., Singh, N., Gadad, A.K., Cameotra, S.S., Badiger, A., Synthesis and anticancer evaluation of novel 2-cyclopropylimidazole[2,1-b][1,3,4]-thiadiazole derivatives. Eur. J. Med. Chem. 46 (2011), 4411–4418.
26. Noolvi, M.N., Patel, H.M., Bhardwaj, V., A comparative QSAR analysis of quinazoline analogues as tyrosine kinase (erB-2) inhibitors. Med. Chem. 7 (2011), 200–212.
27. Noolvi, M.N., Patel, H.M., Bhardwaj, V., Chavan, A., Synthesis and in vitro antitumor activity of substituted quinazoline and quinoxaline derivatives: search for anticancer agent. Eur. J. Med. Chem. 46 (2011), 2327–2346.
28. Noolvi, M.N., Patel, H.M., Kamboj, S., Kaur, A., Mann, V., Eur. J. Med. Chem. 56 (2012), 56–69.
29. Noolvi, M.N., Patel, H.M., Kaur, M., Benzthiazoles: search for anticancer agents. Eur. J. Med. Chem. 54 (2012), 447–462.
30. Phase 1.0 (2005) User manual. Schrodinger, New York.
31. Prathipati, P., Saxena, A.K., Characterization of b3-adrenergic receptor: determination of pharmacophore and 3D QSAR model for β3-adrenergic receptor agonism. J. Comput. Aided Mol. Des. 19 (2005), 93–110.
32. QikProp, version 9.0, Schrodinger, LLC., New York, NY, 2010.
33. Ryan, A.J., Wedge, S.R., ZD647 a novel inhibitor of VEGFR and EGFR tyrosine kinase. Cancer 92 (2005), S6–S13.
34. Scanga, A., Kowdley, K., Sorafenib: a glimmer of hope for unresectable hepatocellular carcinoma?. Hepathology 49 (2009), 332–334.
35. Sepp-Lorenzino, L., Thomas, K.A., Antiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development. Expert Opin. Invest. Drugs 11 (2002), 1447–1465.
36. Shawver, L.K., Lipson, K.E., Fong, T.A.T., McMahon, G., Plowman, G.D., Strawn, L.M., Receptor tyrosine kinases as targets for inhibition of angiogenesis. Drug Discov. Today 2 (1997), 50–63.
37. Sherman, W., Day, T., Jacobson, M.P., Friesner, R.A., Farid, R., Novel Procedure for Modeling Ligand/Receptor Induced Fit Effects. J. Med. Chem. 49 (2006), 534–553.
38. Supuran, C.T., Scozzafava, A., Protein tyrosine kinase inhibitors as anticancer agents. Expert Opin. Ther. Pat. 14 (2004), 35–53.
39. Takahashi, Y., Bucana, C.D., Cleary, K.R., Ellis, L.M., Expression of vascular endothelial growth factor and its receptor, KDR correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 55 (1995), 3964–3968.
40. Tawari, N.R., Bag, S., Degani, M.S., Pharmacophore mapping of a series of pyrrolopyrimidines, indolopyrimidines and their congeners as multidrug resistance-associated protein (MRP1) modulators. J. Mol. Model. 14 (2008), 911–921.
41. Tropsha, A., Oprea, T.I., (eds.) Chemoinformatics in drug discovery, 2005, Wiley, Weinheim, 437–455.
42. Yoshiji, H., Gomez, D.E., Shibuya, M., Thorgeirsson, U.P., Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res. 56 (1996), 2013–2016.
43. Zhong, H., Tran, L.M., Jenna, L., Induced-fit docking studies of the active and inactive states of protein tyrosine kinases. J. Mol. Graph. Mod. 28 (2009), 336–346.